Roughly 10% of COVID-19 patients with severe pneumonia in a cohort of 987 patients had neutralizing autoantibodies against IFNα, IFNω, or both, where patients with no or mild symptoms had no detectable autoantibodies (95). This evidence concerns the gene IFNA2 and susceptibility to pneumonia measurement.